Cocrystal Pharma (NASDAQ:COCP) Stock Rating Reaffirmed by HC Wainwright

Cocrystal Pharma (NASDAQ:COCPGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $10.00 price objective on the stock.

Cocrystal Pharma Price Performance

NASDAQ:COCP opened at $1.45 on Thursday. Cocrystal Pharma has a 1-year low of $1.33 and a 1-year high of $3.29. The stock has a market cap of $14.75 million, a P/E ratio of -0.73 and a beta of 1.34. The firm has a 50-day moving average of $1.50 and a two-hundred day moving average of $1.68.

Cocrystal Pharma (NASDAQ:COCPGet Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.13. As a group, equities analysts expect that Cocrystal Pharma will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. Susquehanna International Group LLP acquired a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCPFree Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 20,728 shares of the company’s stock, valued at approximately $41,000. Susquehanna International Group LLP owned about 0.20% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

(Get Free Report)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Read More

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with's FREE daily email newsletter.